An analysis of FDA-approved drugs for cardiovascular diseases. 2016

Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
Yale Center for Molecular Discovery, West Haven, CT 06516, USA. Electronic address: michael.kinch@yale.edu.

Following the introduction of antibiotic therapy and widespread inoculations, cardiovascular diseases have leapt ahead of infectious diseases in terms of prevalence in much of the developed and developing world. Herein, we assess FDA-approved drugs for the treatment of cardiovascular diseases. The drug development enterprise around cardiovascular diseases has remained stable in contrast to turbulent changes in other therapeutic indications. However, upon closer inspection, the results identify narrow scope in terms of the breadth of targets and the mechanistic actions of new drugs. From the public health point of view, it is important to balance incremental change with orthogonal innovations that are needed to combat a leading cause of morbidity and mortality.

UI MeSH Term Description Entries
D002317 Cardiovascular Agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. Cardioactive Agent,Cardioactive Drug,Cardiovascular Agent,Cardiovascular Drug,Cardioactive Agents,Cardioactive Drugs,Cardiovascular Drugs,Agent, Cardioactive,Agent, Cardiovascular,Drug, Cardioactive,Drug, Cardiovascular
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014486 United States Food and Drug Administration An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. Food and Drug Administration (U.S.),USFDA,Food and Drug Administration,United States Food, Drug Administration
D017277 Drug Approval Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug. Drug Approval Process,New Drug Approval,Food and Drug Administration Drug Approval,Food and Drug Administration Drug Approval Process,New Drug Approval Process,Approval Process, Drug,Approval Processes, Drug,Approval, Drug,Approval, New Drug,Approvals, Drug,Approvals, New Drug,Drug Approval Processes,Drug Approval, New,Drug Approvals,Drug Approvals, New,New Drug Approvals,Process, Drug Approval,Processes, Drug Approval

Related Publications

Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
June 2015, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
August 2015, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
December 2014, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
March 2015, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
September 2015, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
January 2015, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
October 2014, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
October 2023, Digital discovery,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
September 2014, Drug discovery today,
Michael S Kinch, and Yulia Surovtseva, and Denton Hoyer
December 2010, Journal of the National Comprehensive Cancer Network : JNCCN,
Copied contents to your clipboard!